Home
/
ADC Therapeutics SA
/
Financials
/
Quarterly
ADC Therapeutics SA — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ADC Therapeutics SA filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$16.43M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$18.84M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$23.03M
May 14, 2025
Q3
2025
Sep 30, 2024
$18.46M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$17.41M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$18.05M
May 14, 2025
Q3
2024
Sep 30, 2023
$14.49M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$19.28M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$18.99M
May 6, 2024
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$15.75M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$18.09M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$17.40M
May 14, 2025
Q3
2025
Sep 30, 2024
$18.02M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$17.03M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$17.85M
May 14, 2025
Q3
2024
Sep 30, 2023
$14.27M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$19.20M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$18.95M
May 6, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($40.97M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($56.65M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($38.60M)
May 14, 2025
Q3
2025
Sep 30, 2024
($43.97M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($36.54M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($46.61M)
May 14, 2025
Q3
2024
Sep 30, 2023
($46.73M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($48.92M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($59.37M)
May 6, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.97M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($44.15M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($28.46M)
May 14, 2025
Q3
2025
Sep 30, 2024
($35.56M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($29.04M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($33.61M)
May 14, 2025
Q3
2024
Sep 30, 2023
($36.15M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($39.65M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($50.21M)
May 6, 2024